Sage-N Research Introduces First AI Data System for Biopharmaceutical Proteomics
MILPITAS, Calif. - Dec. 4, 2019 - PRLog -- Sage-N Research, Inc., a deep tech and services company, introduces the world's first professional AI-enabled deep data platform for clinical proteomics. Proteomics can save significant time and money in clinical trials and discovery by probing protein pathways, but current software — mostly academic PC downloads — lack useful sensitivity and are prone to costly false positives. AIMS™ ("AI for MS") uses intelligent data mining to increase sensitivity by orders of magnitude while eliminating false positives, which unlocks mass spectrometry's (MS) potential as the digital extension of the nearly $20B immunoassay (ELISA) market.
"Just as a 3D CT scan reveals more subtle features by combining multiple 2D x-rays, AIMS triangulates many relevant data files to characterize ultra-low abundance proteins," according to David Chiang, Sage-N Research founder and chairman. "Our breakthrough technique was recently outlined in well-received scientific posters."
Biopharmaceutical R&D experiments are costly with low productivity because researchers cannot see what is happening in protein pathways when things go wrong. Immunoassays can chemically probe specific protein forms, but they are generally unavailable for low-abundance proteins. In theory, proteomics is a game-changer that can probe practically any MS-detectable protein form, as a representative peptide, using only its amino acid sequence plus post-translational modifications (PTMs). In other words, it is essentially a universal, digitalized immunoassay ("cyber-assay")
High-value clinical projects can be accelerated and saved with professional-